Asia Pacific Breast Cancer Liquid Biopsy Market Size & Outlook
Asia Pacific breast cancer liquid biopsy market, 2018-2030 (US$M)
Related Markets
Asia Pacific breast cancer liquid biopsy market highlights
- The Asia Pacific breast cancer liquid biopsy market generated a revenue of USD 45.2 million in 2021.
- The market is expected to grow at a CAGR of 20.6% from 2022 to 2030.
- In terms of segment, circulating cell-free dna (cfdna) was the largest revenue generating biomarkers in 2021.
- Circulating Tumor Cells (CTCs) is the most lucrative biomarkers segment registering the fastest growth during the forecast period.
- Country-wise, South Korea is expected to register the highest CAGR from 2022 to 2030.
Asia Pacific data book summary
| Market revenue in 2021 | USD 45.2 million |
| Market revenue in 2030 | USD 244.7 million |
| Growth rate | 20.6% (CAGR from 2021 to 2030) |
| Largest segment | Circulating cell-free dna (cfdna) |
| Fastest growing segment | Circulating Tumor Cells (CTCs) |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Circulating Tumor Cells (CTCs), Circulating Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), Other Circulating Biomarkers |
| Key market players worldwide | Menarini Group, NeoGenomics, Roche, Myriad Genetics Inc, Qiagen NV, Biocept Inc, Sysmex Corp, Epic Corp, Thermo Fisher Scientific Inc |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 16.3% of the global breast cancer liquid biopsy market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Europe is the fastest growing regional market and is projected to reach USD 487.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Breast Cancer Liquid Biopsy Market Scope
Breast Cancer Liquid Biopsy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific breast cancer liquid biopsy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer liquid biopsy market will help companies and investors design strategic landscapes.
Circulating cell-free dna (cfdna) was the largest segment with a revenue share of 56.19% in 2021. Horizon Databook has segmented the Asia Pacific breast cancer liquid biopsy market based on circulating tumor cells (ctcs), circulating cell-free dna (cfdna), extracellular vesicles (evs), other circulating biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Asia Pacific breast cancer liquid biopsy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific breast cancer liquid biopsy market databook
-
Our clientele includes a mix of breast cancer liquid biopsy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific breast cancer liquid biopsy market, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific breast cancer liquid biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific breast cancer liquid biopsy market report size, by country, 2018-2030 (US$M)
Asia Pacific Breast Cancer Liquid Biopsy Market Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
